Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Access to land for mobile telecoms networks: a framework for negotiation and regulation
Mobile towers serve as the backbone of mobile telecoms networks, hosting radio access network equipment that enables us to receive calls, texts and to access the internet on our mobile devices. In turn, the ability of the builders of mobile towers to access land—whether that is on the ground,… Read More
Podcasts
What is venture capital, how does it work, and what are the risks?
In the third and final episode demystifying private equity, we explore the world of venture capital. While venture capital has delivered exceptional returns for some investors and founders, it’s also very high risk. So, is vibrant venture capital essential for economies seeking to boost innovation and drive productive growth? In… Read More